Streetbeat News

Analyst Ratings

NRDS

Citigroup analyst Peter Christiansen has maintained a Neutral rating on Nerdwallet (NASDAQ:NRDS) and increased the price target from $11 to $16.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 8:20 pm

MRVL

Citigroup analyst Atif Malik has reaffirmed a Buy rating on Marvell Technology (NASDAQ:MRVL) and increased the price target from $61 to $75.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 8:18 pm

EW

RBC Capital analyst Shagun Singh has reaffirmed an Outperform rating on Edwards Lifesciences (NYSE:EW) and increased the price target from $80 to $82.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 8:04 pm

ISRG

RBC Capital analyst Shagun Singh has maintained an Outperform rating on Intuitive Surgical (NASDAQ:ISRG) and increased the price target from $380 to $400.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 8:01 pm

MDT

Medtronic (NYSE:MDT) has received mixed ratings from 4 analysts in the past three months, with an average 12-month price target of $89.75, slightly down from the previous $90.00. Analysts' actions include both upgrades and downgrades, reflecting varied perspectives on the company's performance. Medtronic is a major medical-device company with a strong market presence, but it faces challenges in revenue growth, ROE, and ROA compared to industry averages, while its net margin and debt management are positive indicators.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 8:01 pm

ZBH

Zimmer Biomet Holdings (NYSE:ZBH) has received mixed analyst ratings over the last quarter, with 10 analysts offering varied sentiments. The recent ratings show 4 somewhat bullish and 6 indifferent, with no bullish or bearish ratings. The 12-month price target average for ZBH is now $128.8, down from $138.11, indicating a 6.74% decrease. Analysts from firms like RBC Capital, Evercore ISI Group, and Morgan Stanley have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. Zimmer Biomet, a leader in orthopedic reconstructive implants, has shown a revenue growth rate of 5.02% as of September 30, 2023, but trails behind industry peers and shows lower profitability and return metrics compared to industry averages.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 8:00 pm

RHP

Analysts have provided varying ratings for Ryman Hospitality Props (NYSE:RHP) over the last quarter, with a recent shift towards a more bullish stance. The average 12-month price target for RHP has increased to $116.0, up from $107.20, with a high estimate of $134.00 and a low of $102.00. Analysts from Truist Securities, Wells Fargo, and JP Morgan have raised their price targets, reflecting positive market dynamics and company performance. Ryman Hospitality Props is a REIT specializing in upscale convention center resorts and country music entertainment, with strong financial indicators such as a 12.99% revenue growth rate and a net margin of 7.8%.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 8:00 pm

SYK

Stryker (NYSE:SYK) has received mixed analyst ratings over the past three months, with 7 analysts offering views ranging from bullish to indifferent. The average 12-month price target for SYK has increased by 10.1% to $324.57, with a high estimate of $345.00 and a low of $297.00. Analysts from RBC Capital, Truist Securities, Morgan Stanley, Roth MKM, and UBS have adjusted their ratings and price targets, reflecting a positive outlook on the company's performance. Stryker is a major player in medical equipment and has shown strong financial indicators such as a 9.6% revenue growth rate, a net margin of 14.1%, and an ROA of 1.83%, but a lower-than-average ROE of 3.92% and a conservative debt-to-equity ratio of 0.71.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 8:00 pm

NDAQ

Analysts have provided mixed reviews on Nasdaq (NASDAQ:NDAQ) over the last three months, with 6 analysts offering ratings ranging from bullish to indifferent. The average 12-month price target is $64.33, with a recent increase from $57.33. Analysts from Citigroup, Goldman Sachs, JP Morgan, Morgan Stanley, Oppenheimer, and Rosenblatt have updated their ratings and price targets. Nasdaq faces challenges with a revenue decline of -6.81%, a below-average net margin, and a high debt-to-equity ratio, but it has a strong ROE.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 8:00 pm

MDT

RBC Capital analyst Shagun Singh has maintained a 'Sector Perform' rating on Medtronic (NYSE:MDT) and increased the price target from $82 to $92.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 7:59 pm